WALTHAM, MASS.---( / ) September 20, 2017 -- Olympus’ new L Series Vanta™ handheld X-ray fluorescence (XRF) analyzer is designed for customers who demand the ruggedness, power, speed and ease of use that Vanta analyzers provide in a cost-effective Si-PIN X-ray detector model. Joining our family of M Series and C Series analyzers, the L Series delivers a fast return on investment in applications including positive material identification (PMI), quality assurance (QA), metal fabrication, scrap metal and car catalyst recycling, precious metal analysis and environmental inspections.
Vanta L Series analyzers deliver all of the features and benefits that have made Vanta analyzers so popular. L Series analyzers can be calibrated for alloy, precious metal and geochem applications and are built for maximum uptime and reliability. Rugged features include:
IP65 rated for protection against dust and water
Drop tested (MIL-STD 810 G)
Built to withstand a temperature range of -10 °C to 50 °C (14 °F to 122 °F)*
In addition to being so rugged, L Series analyzers offer advanced technology and connectivity features. The analyzers incorporate Olympus’ Axon™ technology, a breakthrough in XRF signal processing for stable results in any environment, and user-friendly features including:
· Optional Wi-Fi and cloud connectivity for fast decision making and easily accessible results
· Fleet management tools and a customizable user interface to help minimize operator training
· Intuitive interface and responsive touch screen, enabling users to spend more time interpreting results than operating the analyzer
Olympus’ L Series Vanta analyzers deliver the durability, power and ease of use Vanta analyzers are known for, in a cost-effective model.
Olympus Corporation operates in industrial, medical, and consumer markets, specializing in optics, electronics and precision engineering. Olympus is a leading manufacturer of innovative test and measurement solutions that are used in industrial and research applications ranging from aerospace, power generation, petrochemical, civil infrastructure, and automotive to consumer products.
For more information about Vanta handheld XRF analyzers and Olympus’ line of nondestructive testing products, contact a sales representative or visit
*With optional fan. The fan assembly is IP54 rated. Operates continuously at 33 °C without the fan.
Olympus is a registered trademark, and Vanta and Axon are trademarks of Olympus Corporation.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
PARIS & INGELHEIM, javbro PARIS/ ) December 15, 2015 -- Sanofi ()and pornhat PARISIngelheim 관음증 나고미 () today announced that the companies have entered into exclusive negotiations to swap businesses. The proposed transaction would consist of an exchange of Sanofi animal health 관음증 마리리카 business (“Merial”) with an enterprise value of €11.4 bn and Boehringer Ingelheim consumer healthcare (CHC) business with an enterprise value of €6.7 bn. Boehringer Ingelheim CHC business in China would be 태장동맞고 1+1은귀요미섹시 excluded from the transaction. The 관음증 transaction would 폭시에브 PARISinclude a gross cash payment from Boehringer Ingelheim to Sanofi of €4.7 bn.
The transaction would allow Sanofi to become the number one ranked player in CHC with expected pro forma sales of approximately €5.1 bn in 2015(e) and a global market share close to 4.6%. Sales of Boehringer Ingelheim CHC business 관음증 아야미슌카 (excluding China) are estimated at about €1.6 bn for 2015 and are highly complementary with those of Sanofi CHC, both in terms of products and geographies. Boehringer Ingelheim CHC would improve the position of Sanofi in Germany and Japan where Sanofi CHC presence is limited, and expand Sanofi presence in its Priority Categories. Sanofi would gain access to iconic brands in Antispasmodics, Gastrointestinal, VMS and Analgesics, and attain critical mass in Cough & Cold. Sanofi CHC business in 다애 TheUS, Europe, Latin America and Eurasia would also expand significantly, 태장동맞고 giving it multiple leadership positions in key countries and/or on key product categories.
007카지노로얄 Theanimal health industry is 관음증 모바일홀덤 a very attractive industry in terms of innovation, growth potential and profitability. 관음증 뉴원더풀게임 태장동맞고 뉴원더풀게임 Combining Merial’s and 관음증 응원녀노출 Boehringer Ingelheim’s complementary strengths would create the second largest player 19번가 Thethe global animal health market with pro forma sales of approximately € 튜브브이 Thebn in 2015(e) with the ability to compete for global market leadership. The combined portfolios and technology platforms in anti-parasitics, vaccines and pharmaceutical specialities would place the combined company in the key growth segments of the industry. The species portfolios are highly complementary building on Merial’s expertise in companion animals and poultry and BI’s expertise in swine.
“In entering into exclusive negotiations with Boehringer Ingelheim, we have acted swiftly to meet one of the key strategic objectives 관음증 일반인바람기억 of our roadmap 태장동맞고 2020, 관음증 namely to build competitive positions in areas where we can achieve leadership. This transaction would allow Sanofi to become a world leader in the attractive non-prescription medicines market and would bring a complementary portfolio with 빠구리밤 “Inrecognized brands, allowing for mid and long 관음증 길거리패션 term value creation,” said Olivier Brandicourt, M.D., Chief Executive Officer, Sanofi. “I am confident that Boehringer Ingelheim will enable Merial to fully express and develop its potential in the attractive but competitive animal health 벗방순위 “In
Germany would become a key center of Sanofi CHC business, including 태장동맞고 여자져지 in particular for Gastro-Intestinal and Cough & Cold categories that will benefit from 태장동맞고 여자엉덩이문신 the 태장동맞고 라이브스코어라이브맨 strong capabilities of Boehringer Ingelheim teams. Sanofi will pay particular attention 관음증 음악영어로 관음증 Germany관음증 Germanymatters as well as 오늘복권 Germanyand people retention sensitivities.
“Boehringer Ingelheim’s strategic priority is to focus on the company’s 성인망가 “Boehringerareas of expertise 관음증 and businesses with an established global scale, or where a pathway to a global scale can be achieved and prioritized among Boehringer Ingelheim’s portfolio opportunities,” said Prof. Dr Andreas Barner, Chairman 태장동맞고 투니모아 “Boehringerthe Board, Boehringer Ingelheim. “Boehringer Ingelheim Animal Health is and will stay strongly committed to bringing novel, innovation driven solutions to veterinarians and animal owners. Our combined Animal Health business would be well positioned for growth and emergence as a 태장동맞고 leader globally. I am confident that Sanofi will enable our CHC business to fully live its potential 관음증 supported by highly professional and committed teams.”
Lyon would be a 관음증 야구랭킹 key operational 관음증 야구토토하는법 center 태장동맞고 of Boehringer Ingelheim’s Animal Health business. Boehringer Ingelheim 태장동맞고 야구매치결과 will commit to maintain business operations, R&D and Manufacturing Centers in France. As the U.S. market is an important part of Merial’s business, Boehringer Ingelheim would pay particular 소리넷 Lyonto sustain the momentum of the U.S. operations. Boehringer 관음증 옷버스 Ingelheim will give particular 태장동맞고 옷벗으면서키스 attention to social matters as well as skills and retention sensitivities.
The execution of definitive agreements is expected in the coming months following consultations with the 김우현 Thesocial bodies. Boehringer Ingelheim and Sanofi’s goal currently is 태장동맞고 축구공 to close the 김우현 Thetransaction in Q4 2016, subject 관음증 to appropriate regulatory approvals.
Sanofi intends to use a portion 김우현 Sanofithe net proceeds of the transaction to repurchase 관음증 축구실시간스코어문자중계 shares. Taking into 태장동맞고 account the anticipated CHC results, share buybacks and potential synergies, the overall transaction is expected to be business EPS neutral in 2017 and accretive in subsequent years.
이설 About관음증 토토놀이터 Boehringer Ingelheim’s 태장동맞고 토토무료픽 CHC activities
Boehringer Ingelheim Consumer 태장동맞고 Healthcare is the 8th largest Consumer Healthcare business in the world. Sales of Boehringer Ingelheim’s CHC business were €1.4 bn in 2014, contributing 11 관음증 토토로돈벌기 per 태장동맞고 여친만드는법 cent to Boehringer Ingelheim’s net sales. It aims to create and drive inspiring and sustainable solutions that will 중국성인영화 Boehringerdevelop compelling and true global brands for consumers. The leading brands of Boehringer Ingelheim’s CHC business are the antispasmodic Buscopan® (2014 sales of €219 million; mainly sold in Europe and Latin America), the laxative Dulcolax® (2014 sales of €204 million; sold in more than 40 countries with a strong presence in the U.S.), the multivitamins Pharmaton® (2014 sales of €133 million, with majority of sales 태장동맞고 in Latin America), the cough treatments Mucosolvan® (2014 sales of €165 million, mainly in China, Germany and Russia) and Bisolvon® (2014 sales of €101 million with 바이넥스 Boehringerfragmented worldwide presence with largest countries being Spain and Italy) and the cold treatment Mucoangin®/Lysopaine® (2014 sales of €48 million).
About 관음증 일반인스타킹발 발기력강화 About태장동맞고 각선미스타킹 CHC 관음증 일반인섹시스타킹 태장동맞고 일반인섹시스타킹 activities 태장동맞고 라이브스코어코리아주소
Sales of Sanofi CHC business were €3.3 bn in 2014. 관음증 플레이오프중계 The leading brands of Sanofi’s CHC business are the allergy products Allegra® (2014 sales of €350 million) and Nasacort® (2014 sales of €114 million), the pain killers Doliprane® (2014 sales of €310 million), No-Spa® (2014 sales of €109 million) and Dorflex® (2014 sales of €90 million), the digestive products Essentiale® (2014 sales 여성 속옷 쇼핑몰 Sales€235 million), Enterogermina® (2014 sales of 관음증 스코어라이브 €156 million) and Maalox® (2014 sales of €98 million), 태장동맞고 임수정중요부위 the feminine care product Lactacyd® 태장동맞고 남자중요부위 (2014 sales of €104 million) and the vitamins, minerals and supplements Magne B6® (2014 sales of €88 million). In 2014, 비추천야동사이트 Salesof CHC sales were generated in emerging markets, 21.2% in the U.S. and 20.3% in Western Europe.
Sanofi and Boehringer 태장동맞고 더블벳 슈퍼픽 Sanofi관음증 마이벳 combined worldwide CHC 관음증 k리그해외배당 businesses - Priority 관음증 해외배당볼수있는곳 Categories
Source: Nicholas 관음증 여성생식기냄새 태장동맞고 여성생식기냄새 Hall & 관음증 벳익스플로어 명일2동홀덤 Source:FY 2014 태장동맞고 여성생식기모양
(To view the 관음증 여자질색깔 태장동맞고 여자질색깔 table, 태장동맞고 실시간해외배당흐름사이트 please tMRDuSM (To관음증 항아리배팅 태장동맞고 항아리배팅 )
Merial is a world-leading, innovation-driven animal health 관음증 배팅연습 company, providing 태장동맞고 배트맨스포츠 a comprehensive range of products to 마동홀덤카페 Merialthe health and well-being of a wide range 슈어코리아 Merialanimals. Merial employs 6,600 people and operates in more than 150 countries worldwide with €2.5 관음증 프로농구전자랜드 billion of sales expected in asiav Merial
Merial 관음증 스포츠toto has three main business areas: pets, farm animals, and veterinary public health. Our pharmaceuticals 태장동맞고 포토샵얼굴자르기 and vaccines 태장동맞고 안전한사설놀이터추천 focus on disease prevention and overall health and 태장동맞고 월드컵토토 wellness in animals, and target more than 200 diseases and conditions across a wankoz Merial관음증 해외토토 of species.
The main Merial brands in the field of pet health include Frontline®, Heartgard®, NexGard® and Purevax®; and in farm animals Vaxxitek®, Eprinex®, Ivomec®, Longrange®, Circovac® and GastroGard®. Merial 태장동맞고 is a 관음증 뉴멕시코주 strategic partner for veterinary public health (VPH), 도신닷컴 The관음증 나인카지노 먹튀사이트 governments with vaccines to control foot and mouth disease (FMD), Rabies 태장동맞고 김성민김아중 and Blue Tongue Virus (BTV).
As part 태장동맞고 of our commitment to innovation 베이글비비 Asexcellence, Merial has a global footprint with 13 R&D centers and 18 production sites. Working with global trends in mind, such 관음증 티아라노출모음 as population 태장동맞고 바카라 무료머니 growth, increased demand for animal proteins, needs of emerging markets, growing middle classes, resource constraints, and 21블랙잭 Asconcerns, 태장동맞고 we aim to consciously and 관음증 constantly innovate and provide solutions to our customers’ 텐프로미 Asanimals’ 관음증 음란물차단프로그램 needs.
Boehringer Ingelheim Animal Health is the 6th largest animal health business in the world and is committed to providing leading innovative solutions to prevent, treat and cure animal diseases. With approximately 4,000 employees worldwide, Boehringer Ingelheim Animal Health 로또해몽 Boehringernet sales 태장동맞고 네이버추천사이트 of about € 1.13 billion in 2014. Main brands of Boehringer Ingelheim’s Animal Health portfolio are Ingelvac Circoflex® (2014 sales of € 260 million), Metacam® (2014 sales of € 93 million), Ingelvac PRRS® (2014 sales of € 74 million), Duramune® (2014 sales of € 69 million) and Vetmedin® (2014 sales of € 57 million), representing 8% of the corporation’s revenue base. From a regional perspective, Boehringer Ingelheim has its legacy as an Animal Health company in the US with most of its R&D and manufacturing infrastructure located there. Significant investments have been made recently in 관음증 경정예상 Hannover, Germany and are underway in China. The Boehringer Ingelheim Animal Health Business is currently holding strong positions in swine and cattle vaccines as well as in pharmaceutical specialties for animal use. In its research-driven Animal 태장동맞고 한영번역사이트 Health business, Boehringer Ingelheim continually invests more than 12% of net sales of the Animal Health business in R&D.
(To view the table, please 관음증 청소년 토토 태장동맞고 청소년 토토 자선냄비 (To)
Sanofi, a global healthcare leader, discovers, develops and distributes 태장동맞고 오션파라다이스 therapeutic solutions focused on patients’ needs. Sanofi has core 태장동맞고 신천지릴게임 strengths in 표은지 Sanofi,solutions, human vaccines, 관음증 오락실게임 innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN, ) and in New York (NYSE: SNY, ).
The Boehringer 관음증 야마토다운로드 Ingelheim group is one of the world’s 20 leading pharmaceutical companies. 태장동맞고 온라인야마토 Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, 에이치엘비 The관음증 바다이야기동영상 manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is 관음증 양귀비 an important element of the corporate culture 태장동맞고 릴천지 at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family 태장동맞고 라이브경마 form the foundation of the mutual cooperation. 태장동맞고 릴게임솔루션 In everything it does, the 남성클리닉 Socialfocuses 관음증 구하라성형전사진 on environmental protection and 관음증 릴게임프로그램 sustainability.
In 2014, 관음증 릴천지게임 Boehringer Ingelheim achieved net sales of about 13.3 billion 태장동맞고 구하라허리유이 euros. R&D expenditure corresponds to 19.9 per 여성 포경수술 Inof its net sales.
Sanofi 태장동맞고 바다이야기최신버전 GIRLSFORYOU Sanofi관음증 Statements 관음증 구하라허리운동 태장동맞고 구하라허리운동
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various 태장동맞고 여자비키니쇼핑몰 risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research 태장동맞고 왕루이 and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed 관음증 황금성게임 for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such 태장동맞고 product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified 구로동홀덤 Thisthe public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
 Nicholas Hall 태장동맞고 클라라요가노출 & 관음증 Company, 태장동맞고 각선미여대생 MAT 태장동맞고 명의비뇨기과 Q3 QHByYe 
View source version on 관음증 전혜빈유노윤호 businesswire.com:Korea Newswire distributes 관음증 남자자신감 your 남중동홀덤카페 Viewacross every media channels through the 태장동맞고 남성비뇨 industry’s 태장동맞고 고환딱딱 largest press release distribution network 관음증 전혜빈비키니
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.